StockNews.AI

SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan

StockNews.AI • 13 hours

LMNDILMNTMO
High Materiality10/10

Information

The Company finishes 2025 with strong Q4 performance, expects 20-22% revenue growth in 2026, and pro...

Original source

AI Summary

SOPHiA GENETICS reports Q4 revenue of $21 million, 20% YoY growth. 2026 revenue guidance set at $92-$94 million, 20-22% growth anticipated. Ross Muken promoted to CEO effective July 2026, Jurgi Camblong to Executive Chairman. Strong Q4 performance underpins future growth in U.S. market and BioPharma. Company performed over 105,000 analyses in Q4, signaling increasing demand.

Sentiment Rationale

The strong revenue growth and promising guidance reflect healthy fundamentals. Historical performance shows that similar positive outlooks have typically led to stock price increases.

Trading Thesis

SOPH's strategic plans and strong leadership transition suggest sustained growth opportunities over the long term, enhancing investor confidence.

Market-Moving

  • SOPHiA GENETICS reports Q4 revenue of $21 million, 20% YoY growth.
  • 2026 revenue guidance set at $92-$94 million, 20-22% growth anticipated.
  • Ross Muken promoted to CEO effective July 2026, Jurgi Camblong to Executive Chairman.

Key Facts

  • SOPHiA GENETICS reports Q4 revenue of $21 million, 20% YoY growth.
  • 2026 revenue guidance set at $92-$94 million, 20-22% growth anticipated.
  • Ross Muken promoted to CEO effective July 2026, Jurgi Camblong to Executive Chairman.
  • Strong Q4 performance underpins future growth in U.S. market and BioPharma.
  • Company performed over 105,000 analyses in Q4, signaling increasing demand.

Companies Mentioned

  • LMND (LMND)
  • ILMN (ILMN)
  • TMO (TMO)

Corporate Developments

The leadership update and revenue performance are critical for investors, signaling positive future growth prospects amidst strategic evolution.

SOPHiA GENETICS Reports Strong Q4 2025 Performance and Executive Changes

SOPHiA GENETICS (Nasdaq: SOPH), a leader in AI-driven precision medicine, has announced its preliminary financial results for the fourth quarter and full year 2025. The company is also providing guidance for 2026 and implementing an executive transition plan that promotes Ross Muken to Chief Executive Officer (CEO) on July 1, 2026, while Jurgi Camblong, the co-founder, will take on the role of Executive Chairman.

Fourth Quarter 2025 Financial Highlights

  • Revenue: At least $21 million, showing an approximate 20% year-over-year increase.
  • Analyses Executed: Over 105,000 analyses conducted on the SOPHiA DDM™ platform, marking a 16% growth from the previous year.

Full Year 2025 Performance Overview

  • Annual Revenue: Approximately $77 million, reflecting an 18% year-over-year increase.
  • Record Analyses: More than 391,000 analyses performed on SOPHiA DDM™ throughout 2025.

2026 Guidance

Looking ahead, SOPHiA GENETICS anticipates strong growth for the financial year 2026. The company projects:

  • Projected Revenue: Between $92 million and $94 million, indicating a year-over-year growth of 20% to 22%.
  • Adjusted EBITDA Loss: Expected to be between $29 million and $32 million.

Executive Transition Plan

In a strategic move, Ross Muken will step up as CEO, succeeding Dr. Jurgi Camblong, who will take on the role of Executive Chairman following the company's Annual General Meeting scheduled for June 2026. Dr. Camblong has played a critical role in guiding SOPHiA GENETICS throughout 2025 and will continue to focus on strategic initiatives as Executive Chairman.

SOPHiA GENETICS Board Member Dr. Tomer Berkovitz stated, "These executive changes reflect the Board's and Dr. Camblong's long-term succession planning." Dr. Berkovitz expressed confidence in Muken’s leadership abilities, citing his significant contributions during his tenure.

Leadership Insights

Ross Muken joined SOPHiA GENETICS in February 2021, serving as CFO before his recent promotion to President. He has been instrumental in driving the company's growth and enhancing its commercial organization.

Dr. Camblong remarked on Muken's strategic capabilities, stating, "I am confident he is the right person to lead the company through its next phase of growth."

Upcoming Reporting and Financial Results

SOPHiA GENETICS cautions that the financial results mentioned are preliminary and unaudited. The final results for the fourth quarter and full year 2025 will be reported during the first earnings call in 2026, scheduled for March 3, 2026.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) specializes in leveraging AI for precision medicine, focusing on improving patient care worldwide for cancer and rare disorders. The company is known for its SOPHiA DDM™ platform, which analyzes complex genomic and multimodal data to provide actionable insights across a global network of healthcare institutions.

For further information, visit SOPHiA GENETICS and connect on LinkedIn.

Related News